Effectiveness, immunogenicity and safety of monovalent DS-5670a and bivalent DS-5670a/b SARS-CoV-2 vaccines: results from two randomized, active-comparator, non-inferiority trials

20260 citationsJournal Articlegold Open Access

Authors

This platform can be utilized to produce new vaccines against future SARS-CoV-2 variants.

Good health and well-being

Published in: Communications Medicine

Field-Weighted Citation Impact: 0.00